Live intraday price
Compare with our price levels
Close 2026-09-30: $92.73 · Levels are calculated once a day from the closing price; live prices come from TradingView (may be delayed at times)
Not in the buy zone yet — needs to drop 32.9% · 1 whale recently bought
🎯 Trade plan by price level
Buy in 3 tranches in the buy zone · sell in 3 tranches at the targets · sell everything if the stop-loss breaks
Price levels and picks are calculated automatically with the same formula for every stock — for education only, not a recommendation to buy or sell. · How it's calculated
Risk : reward 1 : 5.3Moves ~$5.56 a day
⚖️ Positives and risks
- ●เซียนซื้อใหม่/ซื้อเพิ่มไตรมาสล่าสุด 1 ราย
- ●แนวโน้มระยะยาวเป็นขาขึ้น (เหนือ MA200 และ MA200 ชี้ขึ้น)
- ●แข็งแกร่งกว่าตลาด (S&P 500) +318% ใน 6 เดือน
- ●นักวิเคราะห์ส่วนใหญ่แนะนำ Buy
- ●เซียนขายออก/ลดสัดส่วน 2 ราย: Bridgewater (ลด), Cathie Wood (ลด)
- ●RSI 79 ซื้อมากเกินไป (Overbought) เสี่ยงย่อตัว
- ●ราคาห่างเหนือ MA200 ถึง +173% วิ่งมาไกลแล้ว
- ●ราคาเกินเป้าหมายนักวิเคราะห์เฉลี่ย 56.60 แล้ว (-39%)
- ●รายได้หดตัว -13% เทียบปีก่อน
- ●บริษัทยังขาดทุน (อัตรากำไรสุทธิติดลบ)
- ●Forward P/E สูง 422 เท่า (คาดหวังการเติบโตไว้มาก)
🕯️ Price chart
Green lines = buy zone E1–E3 · orange = targets T1–T3 · red = stop-loss · arrows = where the paper-trading bot bought/sold
🐋 Whales holding this stock
From each whale's latest quarterly filing
👔 Insider buying & selling
Latest trades from SEC Form 4 filings
Saxonov Serge · CEO · Director
2026-09-22 · 9,900 shares @ $81.83 · pre-planned sale (10b5-1)
Saxonov Serge · CEO · Director
2026-09-22 · 9,300 shares @ $80.90 · pre-planned sale (10b5-1)
Saxonov Serge · CEO · Director
2026-09-22 · 2,800 shares @ $82.37 · pre-planned sale (10b5-1)
SULIMAN SHEHNAAZ · Director
2026-09-22 · 2,270 shares @ $81.67 · pre-planned sale (10b5-1)
Saxonov Serge · CEO · Director
2026-09-22 · 2,000 shares @ $79.62 · pre-planned sale (10b5-1)
SULIMAN SHEHNAAZ · Director
2026-09-22 · 1,325 shares @ $80.82 · pre-planned sale (10b5-1)
SULIMAN SHEHNAAZ · Director
2026-09-22 · 1,222 shares @ $82.28 · pre-planned sale (10b5-1)
Saxonov Serge · CEO · Director
2026-09-22 · 1,000 shares @ $78.23 · pre-planned sale (10b5-1)
SULIMAN SHEHNAAZ · Director
2026-09-22 · 614 shares @ $79.51 · pre-planned sale (10b5-1)
SULIMAN SHEHNAAZ · Director
2026-09-22 · 292 shares @ $78.20 · pre-planned sale (10b5-1)
Taich Adam · CFO
2026-09-09 · 31,428 shares @ $64.31 · pre-planned sale (10b5-1)
Taich Adam · CFO
2026-09-09 · 13,754 shares @ $65.26 · pre-planned sale (10b5-1)
Taich Adam · CFO
2026-09-09 · 1,206 shares @ $63.68 · pre-planned sale (10b5-1)
STUELPNAGEL JOHN R · Director
2026-09-03 · 7,012 shares @ $60.66
STUELPNAGEL JOHN R · Director
2026-09-03 · 6,814 shares @ $62.11
💬 User reviews
Rate and review this stock (sign-in required) — reviews don't affect the system's scores
Loading…
Ratings and comments are each user's own opinion. They don't affect the Smart-Money Score, signals, or price levels and are not investment advice · The average counts each person's latest rating, one vote per person
📰 Latest news
What Needs To Be True To Buy Twist Bioscience Stock Now?
Trefis · 2026-09-25
Surgery Partners, 10x Genomics, QuidelOrtho, Zimmer Biomet, and Tandem Diabetes Stocks Trade Down, What You Need To Know
StockStory · 2026-09-23
Q2 Rundown: 10x Genomics (NASDAQ:TXG) Vs Other Life Sciences Tools & Services Stocks
StockStory · 2026-09-22
Beyond Meta, Cathie Wood’s ARKG Loads Up On These 4 Biotech Names
Stocktwits · 2026-09-22
10x Genomics (TXG) Stock May Look Pricey As Oncology AI News Lands
Simply Wall St. · 2026-09-19
🤖 The paper-trading bot has traded this stock
🔬 Deep dive
For those who want the detailed numbers